Ascendis Pharma A/S (NASDAQ:ASND) Shares Bought by Trexquant Investment LP

Trexquant Investment LP lifted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 235.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,067 shares of the biotechnology company’s stock after buying an additional 19,010 shares during the quarter. Trexquant Investment LP’s holdings in Ascendis Pharma A/S were worth $3,726,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Wilmington Savings Fund Society FSB acquired a new position in Ascendis Pharma A/S during the 3rd quarter worth $30,000. Jones Financial Companies Lllp grew its stake in Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 197 shares in the last quarter. Blue Trust Inc. increased its holdings in Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 328 shares during the last quarter. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the third quarter valued at approximately $60,000. Finally, GAMMA Investing LLC lifted its holdings in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after buying an additional 214 shares during the last quarter.

Analysts Set New Price Targets

ASND has been the topic of several research reports. Cantor Fitzgerald upped their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, February 25th. UBS Group started coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target on the stock. Evercore ISI lifted their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, February 18th. The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus price target of $204.64.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $142.67 on Monday. The stock has a market cap of $8.66 billion, a price-to-earnings ratio of -20.09 and a beta of 0.61. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $169.37. The stock’s 50 day moving average price is $146.39 and its 200 day moving average price is $137.93.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. On average, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.